VVY Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.40 |
52 Week High | €14.50 |
52 Week Low | €0.41 |
Beta | 1.23 |
1 Month Change | 269.60% |
3 Month Change | -71.49% |
1 Year Change | -83.37% |
3 Year Change | -82.42% |
5 Year Change | -52.48% |
Change since IPO | -88.02% |
Recent News & Updates
Recent updates
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 28Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 04Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 02Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
Jan 26Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 16We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth
May 10Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?
Mar 11We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely
Jan 14Shareholder Returns
VVY | NL Biotechs | NL Market | |
---|---|---|---|
7D | 13.5% | 1.6% | -1.8% |
1Y | -83.4% | -10.4% | 16.0% |
Return vs Industry: VVY underperformed the Dutch Biotechs industry which returned -11.7% over the past year.
Return vs Market: VVY underperformed the Dutch Market which returned 16.7% over the past year.
Price Volatility
VVY volatility | |
---|---|
VVY Average Weekly Movement | 51.2% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 3.9% |
10% most volatile stocks in NL Market | 6.7% |
10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: VVY's share price has been volatile over the past 3 months.
Volatility Over Time: VVY's weekly volatility has increased from 26% to 51% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
VVY fundamental statistics | |
---|---|
Market cap | €62.43m |
Earnings (TTM) | -€28.34m |
Revenue (TTM) | n/a |
-17.2x
P/S Ratio-2.2x
P/E RatioIs VVY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VVY income statement (TTM) | |
---|---|
Revenue | -€3.62m |
Cost of Revenue | -€525.00k |
Gross Profit | -€3.09m |
Other Expenses | €25.25m |
Earnings | -€28.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.09 |
Gross Margin | 85.50% |
Net Profit Margin | 782.93% |
Debt/Equity Ratio | 0% |
How did VVY perform over the long term?
See historical performance and comparison